REVEAL Trial: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) Created page with "__NOTOC__ {{High density lipoprotein}} {{CMG}} ==Objective== ==References== {{Reflist|2}} {{Lipopedia}} Category:Lipopedia Category:HDL Category:Clinical trials" |
Rim Halaby (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Objective== | ==Objective== | ||
Start Date: June 2011 | |||
Expected End Date: January 2017 | |||
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)is prospective, randomized, multicenter, placebo-controlled, double-blind clinical trial that will enroll 30,000 patients with high LDL receiving statin therapy. The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems. | |||
==References== | ==References== | ||
Revision as of 03:01, 18 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
REVEAL Trial On the Web |
|
American Roentgen Ray Society Images of REVEAL Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
Start Date: June 2011 Expected End Date: January 2017
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)is prospective, randomized, multicenter, placebo-controlled, double-blind clinical trial that will enroll 30,000 patients with high LDL receiving statin therapy. The study will evaluate the therapeutic effect of anacetrapib 100 mg on lipid profile alteration and role in reduction of cardiovascular morbidity and mortality in patients with baseline circulatory problems.